Kilitch Drugs (India) Limited, founded in 1978 by the visionary entrepreneur Late Mr. Pratap Mehta, who brought over 25 years of invaluable industry experience, has established itself as a notable player in the pharmaceutical domain. The company was officially incorporated as a public limited entity on May 12, 1992, and is registered with the Registrar of Companies, ROC Mumbai, as a non-government company.
As a pharmaceutical company, Kilitch Drugs is actively engaged in the development, manufacturing, marketing, and exporting of a diverse range of pharmaceutical formulations. These span across various dosage forms including solid, liquid, and parenteral products. The company's manufacturing expertise covers a wide spectrum, producing anti-bacterial parenteral formulations and sterile liquid formulations. Its product portfolio includes parenteral and nasal products, oral formulations, effervescent tablets, nutritional supplements, medical devices, and cosmetic and health products. Some of its recognized products include Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE, among others.
Headquartered in Mumbai, India, Kilitch Drugs (India) Limited operates with distinct divisions catering to Over-The-Counter (OTC) and ethical drugs. The company boasts manufacturing facilities strategically located across India, specifically in Ethiopia, the Republic of Yemen, and Patalganga, Maharashtra, India. Its export markets are extensive, reaching countries like Sudan, Yemen, various nations in the Middle East, Miami, and several South American countries.
The company has a dedicated workforce of 168 employees. Its business is primarily structured around a single reportable segment: the development and operation of its pharmaceutical business.
The company has demonstrated robust financial performance over recent periods. For the full fiscal year ended March 2025, Kilitch Drugs reported a significant net profit increase of 82.88%, reaching ₹26.70 crore, compared to ₹14.60 crore in the previous fiscal year ended March 2024. Correspondingly, sales for the full year rose by 28.47% to ₹198.32 crore from ₹154.37 crore in the prior year.
On a quarterly basis, performance has also shown consistent growth. For the quarter ended March 2025, net profit surged by 189.69% to ₹10.40 crore, up from ₹3.59 crore in the same quarter of the previous year. Sales for the quarter increased by 36.61% to ₹61.23 crore, compared to ₹44.82 crore in the corresponding quarter of FY2024.
Further details on quarterly performance indicate sustained growth:
- Q3 FY25: Net profit increased by 104.81% to ₹5.96 crore, with sales growing by 76.69% to ₹56.17 crore.
- Q2 FY25: Sales showed a growth of 15.22% to ₹47.47 crore.
- Q1 FY25: Sales saw a slight decline of 8.51% to ₹33.45 crore.
As of recent data, the company's market capitalization stands at ₹747 crore, marking a substantial increase of 37.2% over the previous year. The Price-to-Earnings (P/E) ratio is reported at 27.40, and the Price-to-Book (P/B) ratio is 4.17.
The stock is currently trading at 3.69 times its book value. The company maintains a strong promoter holding of 69.2%. Despite consistent profitability, the company is not currently distributing dividends. Kilitch Drugs has maintained a sound balance sheet, evidenced by a Return on Equity (ROE) of 9.07% calculated over the last three years.
The Board of Directors has approved a rights issue amounting to ₹49.93 crore. This issue involves offering 13.98 lakh shares at a price of ₹357 per share, with a record date set for July 15, 2025. The entitlement ratio for this rights issue is 2:23, meaning shareholders will be entitled to two rights equity shares for every twenty-three fully paid equity shares they hold. The company plans to allocate the net proceeds from this issue towards funding capital expenditure for a greenfield project located in Pen, Maharashtra, India, and for general corporate purposes.
The leadership team at Kilitch Drugs (India) Limited is headed by Mr. Mukund P Mehta, who serves as the Chairman. Ms. Pushpa Nyoupane holds the position of Company Secretary and Compliance Officer. Key promoters of the company include Mukund P Mehta, Bhavin M Mehta, Hemang Engineer, Mira Bhavin Mehta, Murti Vasudev Krishna, Venkita Subramanian Rajan, Pushpa Nyoupane, and Dipen Jayantilal Jain.
Kilitch Drugs (India) Limited operates within the Healthcare sector, specifically in the Pharmaceuticals sub-sector. Its competitive landscape includes prominent pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, and Mankind Pharma Ltd.
The company remains committed to expanding its pharmaceutical operations, prioritizing quality manufacturing, and reinforcing its global market presence. With a solid financial track record and strategic initiatives like the upcoming rights issue, Kilitch Drugs (India) Limited is well-positioned for sustained growth within the dynamic pharmaceutical industry.
